Valisure’s mission is patient advocacy, consumer protection, and performing advanced research and development to support these endeavors and bring the benefits direct to consumers. Valisure is America’s first pharmacy to chemically validate all its products and do so at no additional cost to consumers.
THE VALISURE STORY
Friends since their Yale days, founders Adam Clark-Joseph and David Light reconnected after Adam suffered serious complications caused by batch variability of his anticonvulsant medication. Shocked that adequate safe guards weren’t in place, he was determined to create a solution. Adam reached out to David, who had a deep background in technology development, in the hopes of forging a path forward. Upon further research, they began to grasp the magnitude and pervasiveness of the problem throughout the pharmaceutical industry. Adam and David brought together a team of like-minded scientists, entrepreneurs, and experts to develop and deploy a solution. The result was Valisure, a company dedicated to preventing anyone from suffering adverse effects from low quality medications.
Founder & Chief Executive Officer
David is a biotech entrepreneur and scientist with over 10 years of broad experience in the field. A graduate of Yale University, David studied molecular biology and has worked in a variety of scientific and business roles at start-ups like Synthetic Genomics, 454 Life Sciences and Ion Torrent. At Ion, David developed key technologies that led to its $725M acquisition and ran its flagship technology programs through development and global commercialization.
DAVID GORTLER, PharmD, FCCP
Founder & Chief Medical Officer
Dr. David Gortler is a professor of pharmacology, a former FDA medical officer/senior medical analyst and an expert in the area of drug safety, FDA policy, and drug importation. Dr. Gortler has been invited to testify in front of the U.S. Senate as a drug policy expert, FDA expert and pharmacology expert. He has two decades of investigational medicine and drug safety experience, and over a decade of teaching and research at top-tiered medical schools (Yale University, Georgetown University, and George Washington University).
KAURY KUCERA, PhD
Chief Scientific Officer
Dr. Kaury Kucera has managed scientific challenges at Yale University as a Molecular Biophysics and Biochemistry Graduate Student, Postdoctoral Fellow, and Research Scientist in the Department of Pharmacology. A scientist and problem-solver, Kaury was the research director for a $2.5M HHMI matched grant program and personally oversaw development of 200+ unique assays to investigate bioactive molecules.
Chief Marketing Officer
Daniel has managed marketing challenges with extensive experience on both the agency and the vendor side. He has hands-on experience leading work on world class brands like Nike, Facebook, Coca-Cola, Amazon, and many others in North America, Central America, Europe and Asia. Daniel is SVP at The Palmerston Group, a regular instructor at Miami Ad School and a frequent speaker at industry conferences. Daniel holds a BA in psychology from McGill University and a masters in advertising from The University of Texas at Austin.
ADAM CLARK-JOSEPH, PhD
Adam is an assistant professor of finance at the University of Illinois at Urbana-Champaign. He holds a PhD in economics from Harvard, a master’s degree from Cambridge, and bachelor’s degrees in math and economics from Yale. Adam was the recipient of a NSF Graduate Research Fellowship and a Gates Cambridge Scholarship. His academic research focuses on algorithmic trading, and empirical applications of high-performance computing and novel statistical methods.
Bob is Director of Platform Development at Harvard University, responsible for the implementation of commercialization and technology translation strategies. His industry experience with Haemonetics, endoVia Medical, RainDance Technologies, and Hemocell includes founder, CEO and other executive roles in companies commercializing innovative technologies. He holds a degree in Biochemistry from the University of California at San Diego and is a member of the Massachusetts Biotechnology Industry Council.
Wolfgang is a senior director in the Clinical Sequencing Division of Thermo Fisher Scientific with over 16 years of experience in technology development. A graduate of the University of Cape Town, Wolfgang conducted research as a postdoctoral fellow at Yale University in Physical Organic Chemistry and Pharmacology. Wolfgang is passionate about the use of technology to solve problems in public health and is named inventor on 30+ granted patents and 70+ patent applications.